Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2003-09-16
2004-09-07
Richter, Johann (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C560S227000, C570S134000
Reexamination Certificate
active
06787664
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of Invention
This invention relates to a method of preparing L- and D-5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs thereof, including compounds having a protected amino functional group, compounds having a protected carboxy functional group, and compounds having protected amino and carboxy functional groups. These compounds are useful for the preparation of fluorous peptides and proteins.
2. Discussion
Hexafluoroleucine is of considerable interest as an extensively fluorinated analog of leucine that may be used as a building block in the design of fluorous proteins and peptides (E. N. G. Marsh, 7
Chem. Biol
. R153 (2000)). Fluorocarbons have long been known for their chemical inertness, and their unique physicochemical properties have found industrial and medical uses as fire retardants, refrigerants, anesthetics and biologically inert polymers. The tendency of extensively fluorinated, or fluorous, organic molecules to partition into perfluorinated solvents has been exploited in organic synthesis to facilitate purification of products from reaction mixtures (I. T. Horvath, 31
Acc. Chem. Res
. 641 (1998); Z. Y. Luo et al., 291
Science
1766 (2001)).
Recently, there has been much interest in whether the novel properties exhibited by fluorocarbon polymers can be exploited in the design of biological macromolecules. Extensively fluorinated analogs of hydrophobic amino acids, when substituted into proteins and peptides, pack into the hydrophobic core of the protein to produce proteins that combine novel physicochemical properties with biological activity (Y. Tang et al., 40
Biochemistry
2790 (2001)). Peptides designed to form dimeric coiled-coil structures based on the “leucine zipper” domain of the transcription factor GCN4, or de-novo designed sequences that incorporate (4R, 4S)-L-trifluoroleucine, (3R, 3S)-L-trifluorovaline or L-hexafluoroleucine, display increased stability, enhanced self association and stronger receptor-ligand binding than their non-fluorinated counterparts.
Hexafluoroleucine (hFLeu) is a highly fluorinated analog of leucine, an amino acid that plays an important role in the folding of many proteins. A racemic synthesis of hexafluoroleucine was reported in 1968, and the first chiral synthesis of this amino acid was reported in 1998 (J. Lazar & W. A. Sheppard, 11
J. Med. Chem
. 138 (1968); C. Zhang et al., 81
Helv. Chem. Acta
174 (1998)). The highest enantiomeric purity achieved in this prior work was 81% e.e. and this weakness substantially limits the value of the route for the production of hFLeu for peptide synthesis. More recently, Kumar and coworkers (X. Xing et al., 3
Org. Lett
. 1285 (2001)) reported a ten-step synthesis of L-hFLeu from D-serine. This synthesis was reported to provide L-hFLeu in >51% yield and >99% e.e. from Gamer's aldehyde, which in turn is prepared from D-Serine in five steps. This synthesis is long, difficult to reproduce, and provides material whose enantiomeric purity cannot be demonstrated using the method described. In addition, Garner's aldehyde is an expensive starting material, currently costing about $100 per g.
SUMMARY OF THE INVENTION
The present invention provides a comparatively short and efficient method for preparing L-5,5,5,5′,5′,5′-hexafluoroleucine (L-hFLeu) and its protected analogs from commercially available and inexpensive starting materials, including N-Cbz-L-serine. The claimed method can also be used to prepare D-hFLeu and its protected analogs by utilizing starting materials having opposite stereochemistry (e.g., N-Cbz-D-serine). Hexafluoroleucine and its protected analogs are useful for preparing fluorous peptides and proteins having known utility.
One aspect of the present invention provides a method of making a compound represented by Formula I,
or a corresponding stereoisomer having opposite stereochemistry of Formula I, which can be represented by Formula I′,
In Formula I and Formula I′, R
1
and R
2
are, respectively, N-terminal and C-terminal protecting groups. The method includes providing a compound having a tertiary hydroxy group as represented by Formula IV,
or providing a corresponding stereoisomer having opposite stereochemistry of Formula IV, and displacing the tertiary hydroxy group to yield the compound of Formula I or its corresponding stereoisomer (Formula I′). The method optionally includes de-protecting the compound of Formula I or its corresponding stereoisomer by replacing R
1
or R
2
or both R
1
and R
2
with a hydrogen atom.
Another aspect of the present invention provides a method of making the compound of Formula IV or its corresponding stereoisomer. The method includes reacting a compound of Formula III,
or a corresponding stereoisomer having opposite stereochemistry of Formula III, with zinc to form an organozinc reagent, and subsequently reacting the organozinc reagent with hexafluoroacetone to yield the compound of Formula IV or its corresponding stereoisomer.
A further aspect of the present invention provides a method of making the compound of Formula I or its corresponding stereoisomer (Formula I′), which includes reacting a compound of Formula II,
or a corresponding stereoisomer having opposite stereochemistry of Formula II, with an iodinating agent to yield the compound of Formula III or its corresponding stereoisomer. The iodide is subsequently reacted with zinc to form an organozinc reagent, which in turn is reacted with hexafluoroacetone to form the compound of Formula IV or its corresponding stereoisomer. The compound of Formula IV and its corresponding stereoisomer have a tertiary hydroxy group, which is displaced using radical deoxygenation to yield the compound of Formula I or its corresponding stereoisomer. The method optionally includes de-protecting the compound of Formula I or its stereoisomer by replacing R
1
or R
2
or both R
1
and R
2
with a hydrogen atom.
An additional aspect of the presented invention includes synthetic intermediates, which can be used to prepare the compounds of Formula I and Formula I′. These intermediates include compounds having structures represented by Formula IV or stereoisomers having opposite stereochemistry of Formula IV.
REFERENCES:
Marsh, E.N.G., et al, “Towards the nonstick egg: designing fluorous proteins”, Chem. Biol., (2000), pp. R153-157, vol. 7.
Horvath, I., et al., “Fluorous Biphase Chemistry”, Acc. Chem. Res., (1998), pp. 641-650, vol. 31.
Luo, Z.Y., et al, “Fluorous Mixture Synthesis: A Fluorous-Tagging Strategy for the Synthesis and Separation of Mixtures of Organic Compounds”, Science, (2001), pp. 1766, vol. 291.
Tang, Y. et al., “Stabilization of Coiled-Coil Peptide Domains by Introduction of Trifluoroleucine”, Biochemistry (2001), pp. 2790-2796, vol. 40.
Lazar, J., “Fluorinated Analogs of Leucine, Methionine, and Valine”, J. Med. Chem., (1968), pp. 138-140, vol. 11.
Zhang, C., et al., “Asymmetric Synthesis of (S)-5,5,5,5′,5′,5′-Hexafluoroleucine”, Helv. Chem. Acta, (1998), pp. 174-181, vol. 81.
Xing, X. et al, “A Novel Synthesis of Enantiomerically Pure 5,5,5,5′,5′,5′-Hexafluoroleucine”, Org. Lett., (2001), pp. 1285-1286, vol. 3, No. 9.
Barton, D.H.R., et al, “A New Method for the Deoxygenation of Secondary Alcohols”, J. Chem. Soc. Perkin Trans. 1, (1975), pp. 1574-1585, vol. 1.
Robins, M.J., “Smooth and Efficient Deoxygenation of Secondary Alcohols, A general Procedure for the Conversion of Ribonucleosides to 2′-Deoxynucleosides”, J. Am. Chem. Soc., m(19:1), pp. 932-933, vol. 103.
Robins, M.J., “Nucleic Acid Related Compounds, 42, A General Procedure for the Efficient Deoxygenation of Secondary Alcohols, Regiospecific and Stereoselective Conversion of Ribonucleosides to 2′-Deoxynucleotides”, J. Am. Chem. Soc., (1983), pp. 4059-4065, vol. 105.
Dolan, S. C., et al, “A New Method for the Deoxygenation of Tertiary and Secondary Alcohols”, J. Chem. Soc. Chem. Commun., (1985), pp. 1588-1589.
Anderson James T.
Marsh Edward Neil
Toogood Peter Laurence
Puttlitz Karl
Richter Johann
Russo Matthew J.
Warner-Lambert Company LLC
LandOfFree
Process for preparing single enantiomers of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for preparing single enantiomers of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing single enantiomers of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3223408